Copertina

Diagnostic Performance of Serum Autotaxin for Staging Liver Fibrosis: A Comparative Study With Other Noninvasive Liver Fibrosis Tests in Chronic Liver Disease

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Hideyuki Tamai, Jumpei Okamura
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Hepatology Research
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Microwave Thermosphere Ablation Versus Radiofrequency Ablation in Hepatocellular Carcinoma: Optimizing Treatment Strategies for Tumor Size and Malignancy Grade
di: Hideyuki Tamai, et al.
Pubblicazione: (2025)

Digital Polymerase Chain Reaction‐Based Fecal Streptococcus Quantification for Liver Fibrosis Assessment in Chronic Liver Disease
di: Nomura Nao, et al.
Pubblicazione: (2025)

Association Between Liver Fibrosis and Cause‐Specific Mortality in Japanese Patients With Biopsy‐Confirmed Metabolic Dysfunction–Associated Steatotic Liver Disease: A Prospective Cohort Study / Liver Fibrosis and Mortality in Japanese MASLD
di: Kyoko Sakai, et al.
Pubblicazione: (2025)

Guidance for Liver Rehabilitation in Chronic Liver Disease
di: Shuji Terai, et al.
Pubblicazione: (2026)

Diagnostic Impact of Two‐Dimensional Shear Wave Elastography for Liver Fibrosis: A Multicenter Retrospective Study
di: Takashi Nishimura, et al.
Pubblicazione: (2026)

Young Adults Are at Highest Risk of Liver Fibrosis and Mortality Associated With Steatotic Liver Disease With Metabolic Dysfunction and Alcohol Consumption
di: Jesse Pustjens, et al.
Pubblicazione: (2025)

Noninvasive Assessment of Liver Fibrosis and Steatosis in Liver Transplantation: Commentary on the Diagnostic Value of MR Elastography and MRI‐PDFF
di: Jinxin Chen
Pubblicazione: (2026)

Fibrosis‐4 Index as a Robust Long‐Term Predictor of Cancers in Metabolic Dysfunction–Associated Steatotic Liver Disease
di: Ayumi Kanamoto, et al.
Pubblicazione: (2026)

Elevation of Immunoglobulin Free Light Chain and BAFF Levels Associated With Immune Activation Predicts Survival Rates in Chronic Liver Disease
di: Motoh Iwasa, et al.
Pubblicazione: (2025)

Imaging‐Based Surveillance of Gastroesophageal Varices in Fontan‐Associated Liver Disease: Toward a Noninvasive Strategy
di: Tadashi Namisaki, et al.
Pubblicazione: (2025)

Development of Simplified Risk Assessment Scoring System for Sarcopenia in Patients With Chronic Liver Disease
di: Atsushi Hiraoka, et al.
Pubblicazione: (2025)

Chronic Kidney Disease Risk Associated With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Cohort Study in Korea
di: Dong Wook Kim, et al.
Pubblicazione: (2025)

The Impact of Inflammatory Markers on Prognosis in Advanced Chronic Liver Disease: Insights From a Prospective Cohort Study
di: Jing Liu, et al.
Pubblicazione: (2025)

Liver Transplantation in Japan: Registry by the Japanese Liver Transplantation Society
di: Koji Umeshita, et al.
Pubblicazione: (2026)

Liver Volumetry Enhances Prediction of Acute Pancreatitis in Acute Liver Failure: A Nationwide Registry Study
di: Keisuke Kakisaka, et al.
Pubblicazione: (2025)

Post‐COVID‐19 Changes in Body Composition and Adiposity in Patients With Chronic Liver Disease: A Longitudinal Study From Japan
di: Akira Uchiyama, et al.
Pubblicazione: (2025)

The Nara Declaration: A New Collaborative Flow for Chronic Liver Disease Between Primary Care Physicians and Gastroenterologists/Hepatologists
di: Takumi Kawaguchi, et al.
Pubblicazione: (2025)

Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction–Associated Steatotic Liver Disease
di: Meng‐Lun Hsieh, et al.
Pubblicazione: (2026)

Steatotic Liver Disease and the “Point of No Return” in the Development of Metabolic Disorders
di: Tsutomu Nishida, et al.
Pubblicazione: (2026)

Comment on “Using Serum Creatinine‐to‐Cystatin C Ratio to Predict Sarcopenia in Patients With Liver Cirrhosis”
di: Weiming Wang, et al.
Pubblicazione: (2026)

Initial Experience With Nalmefene in Alcohol‐Related Liver Disease: A Real‐World Retrospective Study
di: Junichi Hanatani, et al.
Pubblicazione: (2025)

Variability in Liver Disease Progression and Outcomes in Glycogen Storage Disease Type IV
di: Rebecca L. Koch, et al.
Pubblicazione: (2026)

Aspirin for Primary Prevention in Metabolic Dysfunction‐Associated Steatotic Liver Disease
di: Oguzhan Celik, et al.
Pubblicazione: (2026)

Comment on “Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction‐Associated Steatotic Liver Disease”
di: Klara Morzone, et al.
Pubblicazione: (2026)

Comment on “Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction‐Associated Steatotic Liver Disease”
di: Hong‐Wei Zheng, et al.
Pubblicazione: (2026)

Employment Status of Patients With Liver Disease: A Nationwide Questionnaire Survey in Japan
di: Yoshio Tokumoto, et al.
Pubblicazione: (2025)

Response to the Letter “Steatotic Liver Disease and the ‘Point of No Return’ in the Development of Metabolic Disorders”
di: Yoshihiro Kamada
Pubblicazione: (2026)

Response to “Aspirin for Primary Prevention in Metabolic Dysfunction‐Associated Steatotic Liver Disease”
di: Tsubasa Tsutsumi, et al.
Pubblicazione: (2026)

Platelet Proteomics: A Glimpse Into Metabolic Dysfunction‐Associated Steatotic Liver Disease Pathogenesis
di: Iulia Minciuna, et al.
Pubblicazione: (2025)

Characteristic Hepatic Atrophy in Abemaciclib‐Induced Liver Injury: A Comparative Review of Three Cases
di: Yuwa Ando, et al.
Pubblicazione: (2026)

The Role of Macrophage Polarization and Ferroptosis in the Progression of Liver Fibrosis
di: Jeri Nobia Purnama, et al.
Pubblicazione: (2025)

Steatotic Liver Disease: A Key Related Risk Factor in the Emergence of Metabolic Syndrome‐Related Disorders
di: Yoshihiro Kamada, et al.
Pubblicazione: (2025)

Extrahepatic Events in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease and the Impact of Genetics and Alcohol Intake
di: Tomomi Kogiso, et al.
Pubblicazione: (2025)

Canagliflozin Alleviates Metabolic Dysfunction‐Associated Steatotic Liver Disease via Mitochondrial Protection and Enhanced Mitophagy
di: Ming Lu, et al.
Pubblicazione: (2025)

Evidence‐Based Clinical Practice Guidelines for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) 2026
di: Norio Akuta, et al.
Pubblicazione: (2026)

Is Glucose Intolerance a Precursor of Cachexia in Patients With Liver Cirrhosis?
di: Tsutomu Nishida, et al.
Pubblicazione: (2025)

Obesity Decreases Liver‐Related Death in Patients With Cirrhosis: A Retrospective Propensity Score‐Matched Study
di: Kei Endo, et al.
Pubblicazione: (2025)

Letter to the Editor: Steatotic Liver Disease: A Key Related Risk Factor in the Emergence of Metabolic Syndrome‐Related Disorders
di: Jianing Hou, et al.
Pubblicazione: (2026)

Response to the Letter “Steatotic Liver Disease: A Key Related Risk Factor in the Emergence of Metabolic Syndrome‐Related Disorders”
di: Yoshihiro Kamada
Pubblicazione: (2026)

Surgical Resections for Hepatocellular Carcinomas Arising From Fontan‐Associated Liver Disease; Open, Laparoscopic and Robotic Hepatectomies
di: Takashi Motomura, et al.
Pubblicazione: (2026)